Health
NHS Rolls Out New Anti-Smoking Drug to Boost Quit Rates Amid Push for a Smoke-Free UK
England’s National Health Service (NHS) has reintroduced an enhanced anti-smoking drug, Varenicline, aimed at increasing success rates for those seeking to quit smoking. Marketed as a prescription-only treatment, Varenicline offers an effective alternative to nicotine-replacement therapies like gum or patches and is comparable to vaping in its ability to curb smoking habits, according to NHS England.
The drug, taken daily, is reported to both reduce nicotine cravings and block the pleasurable effects of smoking on the brain. By minimizing withdrawal symptoms such as irritability and insomnia, Varenicline is seen as a promising tool in the NHS’s suite of smoking cessation options. When paired with counseling or other psychotherapeutic support, NHS data suggests that around 25% of users successfully quit smoking for six months or longer.
The reintroduction of Varenicline is expected to have a substantial public health impact. Research from University College London (UCL) indicates that the drug could assist more than 85,000 people in quitting smoking each year and could prevent up to 9,500 smoking-related deaths over the next five years.
“Prevention is better than cure,” said Wes Streeting, the UK’s Health and Social Care Secretary, in a statement regarding the drug’s rollout. “The availability of this pill can save the NHS millions, speed up appointment availability for other patients, and save lives.”
Previously available under the brand name Champix, Varenicline was withdrawn from NHS prescriptions in 2021 due to the detection of an impurity. However, the newly launched version has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), confirming its safety and efficacy.
NHS Chief Executive Amanda Pritchard emphasized Varenicline’s role in the NHS’s preventive healthcare focus during a speech at the NHS Providers annual conference. “This simple daily pill could be a game-changer for those looking to quit smoking and marks another significant step toward prevention,” she said. “Smoking remains one of the biggest public health issues, impacting the lungs, heart, blood, and brain, and increasing the risk of serious conditions such as cancer and diabetes.”
The launch of Varenicline aligns with the UK’s broader anti-smoking goals, which include a proposed bill to prevent individuals born after January 1, 2009, from legally purchasing cigarettes. Currently, about 12% of adults in the UK smoke, a figure that correlates with over 400,000 smoking-related hospital admissions in England from 2022 to 2023.
The NHS already offers various smoking cessation options, including nicotine replacement therapies and the antidepressant Bupropion (Zyban), which has been shown to reduce cravings. While vaping is also commonly used, it remains unavailable through NHS prescriptions. The National Institute for Health and Care Excellence (NICE) instead recommends licensed stop-smoking medications like Varenicline.
Professor Nick Hopkinson, a respiratory medicine expert at Imperial College London, described Varenicline as “the most effective smoking cessation medication” and emphasized that pairing it with counseling support can improve quit success rates. Dr. Sarah Jackson, principal research fellow at the UCL Tobacco and Alcohol Research Group, added that Varenicline’s availability “can help more people avoid years of ill health and early death.”
With the NHS spending £2.5 billion annually on smoking-related health issues, the reintroduction of Varenicline is viewed as a cost-saving initiative with the potential to improve public health outcomes significantly. As the UK continues its push towards becoming smoke-free, Varenicline offers a new hope for smokers looking to quit and contribute to the nation’s ambitious health goals.
Health
AI Speeds Up Ebola Response in Congo, but Experts Warn of Healthcare Risks
Artificial intelligence is helping health authorities respond more quickly to the Ebola outbreak in the Democratic Republic of Congo (DRC), cutting the time needed to prepare a situation report from a full working day to about an hour. However, experts warn that concerns over transparency, reliability and accountability must be addressed before the technology becomes more widely used in healthcare.
Since May, health workers in the DRC have been responding to an outbreak of the Bundibugyo strain of the Ebola virus. Teams visit communities, provide advice, record deaths and recoveries, and refer people with suspected symptoms to medical facilities.
Information collected by these workers has been digitised and analysed using Anthropic’s Claude artificial intelligence model. The initiative involved the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization’s Regional Office for Africa and the country’s National Institute of Biomedical Research (INRB).
The system helps identify people who may have been exposed to the virus, trace contacts and locate potential outbreak hotspots. This information allows authorities to prepare medical supplies and position resources in areas considered at higher risk.
Marie Roseline Darnycka Belizaire, director for emergency preparedness and response at the WHO Regional Office for Africa, said the technology had reduced the time required to produce situation reports to around one hour.
Speaking at the World Health Summit, she said AI could help health authorities assess the spread of an outbreak more quickly and direct medical assistance where it was needed most.
Supporting overstretched healthcare systems
Thomas Zapata, director of the WHO Academy in Lyon, said AI could help address growing demand for healthcare amid persistent shortages of medical staff and resources.
However, he cautioned against treating the technology as a solution in itself, arguing that it must be integrated into existing health systems and support the work of healthcare professionals.
AI could reduce administrative workloads, improve diagnostic processes and assist clinical decision-making, allowing medical staff to spend more time examining patients, listening to their concerns and arranging appropriate treatment.
Cecilia Mbaka, a senior technical adviser for health and emergencies at aid organisation CARE, said the technology could be particularly useful for repetitive tasks and information processing. She stressed that its value should be measured by whether it improves care and gives medical professionals more time to attend to patients.
In the DRC, however, shortages of equipment and limited public confidence in healthcare facilities remain major challenges. Epidemiologist Maximilian Gertler has estimated that around half of deaths in villages occur outside medical facilities, highlighting difficulties in accessing formal care.
Germany recently increased its assistance to the country by €21 million.
Questions over transparency and reliability
Despite the potential benefits, experts warn that many AI systems cannot clearly explain how they reach particular results.
Thomas Thesen, a professor of medical education and informatics at Dartmouth University’s Geisel School of Medicine, said AI models were highly effective at identifying patterns but often struggled to explain what those patterns meant.
This creates concerns when AI systems offer diagnoses or treatment recommendations. Medical professionals need to assess whether a recommendation is appropriate for an individual patient and understand its limitations. Questions also remain over who should be held responsible when an AI-generated recommendation is wrong.
AI should not replace medical education
Experts also warn that excessive reliance on AI could weaken the training of future healthcare professionals.
Thesen cited research suggesting that students who used AI chatbots to find information developed more superficial knowledge than those who relied on conventional search methods.
He said independent learning and mental effort were essential to retaining information, particularly in medicine, where professionals must make decisions even when technological assistance is unavailable.
The Ebola response demonstrates how AI can help process information quickly during emergencies. Experts say its wider use in healthcare will depend on maintaining human oversight, protecting patients and ensuring that technology strengthens, rather than replaces, professional judgement.
Health
Portuguese Teenagers Report Lower Drug and Alcohol Use, but High-Risk Behaviour Persists
Portuguese teenagers are reporting lower levels of alcohol and drug use and fewer problems linked to addictive behaviours, but risks are becoming increasingly concentrated among young people facing multiple personal and social difficulties, according to a new study.
The findings come from the 2024 Study on Alcohol, Tobacco, Drugs and Other Addictive Behaviours (ECATD-CAD), conducted by the Institute for Addictive Behaviours and Dependencies (ICAD). The research examines addictive behaviours among pupils aged 13 to 18 attending state schools across Portugal.
Compared with the previous study in 2019, the latest results show a consistent decline in reported problems, including violence, accidents, hospitalisations, risky sexual behaviour and other incidents with potentially serious consequences.
Researchers linked the broader improvement to several protective factors. Students reported better academic performance, closer parental supervision and fewer nights out, suggesting that changes in family and school environments may be helping reduce risky behaviour.
However, ICAD warned that the overall decline does not mean the problem has disappeared. The most serious behaviours are increasingly concentrated in a relatively small group of adolescents who face greater individual and social vulnerabilities.
Recent alcohol consumption and, particularly, illicit drug use remain strongly associated with problematic situations. Young people who use psychoactive substances report higher rates of risky sexual behaviour, violence between individuals, accidents and trouble with the police.
The report noted that these problems do not necessarily occur immediately after substance use, but the association remains significant.
Combining alcohol with illicit drugs appears to carry additional risks. Adolescents who reported recent use of both substances experienced higher levels of accidents, police-related problems, cyberbullying and risky sexual behaviour than those who consumed alcohol alone.
Alcohol use also raises concerns about why some teenagers drink. While pleasure, entertainment and socialising remain the main motivations, a significant proportion said they consumed alcohol to forget their problems. ICAD identified this as a warning sign associated with potentially harmful drinking patterns and dependence.
Cannabis use presented a mixed picture. Although most users showed no indicators of dependency risk, the proportion classified as being at high risk increased, alongside growth in the group with no identified risk.
Social media remained the main concern among behaviours not involving substances. A significant number of young people acknowledged spending excessive time on these platforms. Indicators of problematic electronic gaming remained broadly stable, while gambling for money became more prevalent among adolescents, despite a slight decline in some indicators of problematic gambling.
The study also identified differences between boys and girls. Boys were more likely to report problems with the police, risky gaming and gambling. Girls reported higher levels of problematic social media use and were more likely to use alcohol to cope with emotional difficulties.
Family circumstances and wellbeing were also important. Low academic achievement, limited parental supervision, frequent nights out and poorer physical and emotional health were associated with greater risk. Better school performance, stronger parental involvement and improved wellbeing appeared protective.
Regional differences were also evident. Alentejo recorded the highest concentration of unfavourable indicators, followed by the Azores. Lisbon, which showed the greatest vulnerability in the 2019 study, no longer held that position.
ICAD’s findings point to the need for targeted support for vulnerable adolescents, even as overall patterns of substance use and related problems improve.
Health
Plague Fears Return After Russian Death, but Europe Faces Very Low Risk
The death of a scientist in Russia’s Siberian region of Irkutsk has revived concerns about plague, but health authorities say there is currently no evidence of an outbreak or sustained transmission in Europe.
The woman died from pneumonia of unknown origin, prompting speculation that she could have contracted pneumonic plague. Russian authorities have said no plague cases have been confirmed in the region, while tests conducted on people who had contact with the woman were negative.
The World Health Organization has asked Russia for additional information about the incident and offered assistance to local health authorities.
Plague is caused by the bacterium Yersinia pestis, which remains present in wild animal populations in parts of the world. It is commonly associated with rodents and the fleas that live on them. People can become infected through bites from infected fleas, contact with tissues or bodily fluids from infected animals, or respiratory particles from people suffering from pneumonic plague.
For Spain and most of Europe, however, the current risk is considered very low. The European Centre for Disease Prevention and Control says routine transmission has not been recorded in Europe for more than five decades.
That does not mean the bacterium has disappeared. Its continued presence in animal reservoirs means isolated human infections remain possible, particularly in areas where infected wildlife and fleas are found.
Spain has maintained epidemiological surveillance despite the absence of locally acquired cases for decades. In April 2026, its Public Health Commission updated the national plague protocol, including case definitions, epidemiological information and procedures for investigating suspected infections.
European authorities have also been monitoring the Siberian incident. The European Union discussed the case at a Health Security Committee meeting on October 7, while the ECDC said there was no evidence of secondary cases or sustained person-to-person transmission.
The WHO has assessed the risk to the European region as very low.
Plague continues to occur in parts of Africa, Asia and the Americas. According to the WHO, most reported human cases between 2019 and 2025 were concentrated in Madagascar and the Democratic Republic of the Congo. Madagascar records bubonic plague cases during its annual epidemic season, generally from September to April. In the United States, about seven human cases are reported each year, mainly in rural areas of western states.
The disease can occur in bubonic, pneumonic or septicaemic forms. Bubonic plague usually causes fever and painful swollen lymph nodes after an infected flea bite. Pneumonic plague affects the lungs and can spread between people through respiratory particles. Septicaemic plague occurs when the infection enters the bloodstream.
Modern antibiotics can successfully treat plague, but early diagnosis is critical. Health surveillance, rapid identification and treatment remain important in preventing isolated infections from developing into wider outbreaks.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement2 years agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
